UCL Cancer Institute


Welcome to the UCL Cancer Institute 

The UCL Cancer Institute is the hub for cancer research at University College London, one of the World's leading universities. The Institute draws together over 300 talented scientists who are working together to translate research discoveries into developing better, more effective therapies for cancers and improve outcomes for cancer patients. If you are thinking about postgraduate study with us, applications to our flagship MSc Cancer programme are now open for the academic year 2017/18, or find our more about our postgraduate research

News and features

Landmark study provides insight into chemotherapy treatment for lung cancer patients

A research team, led by UCL, has published the results of a highly anticipated clinical trial comparing platinum and non-platinum chemotherapy in the Journal of Clinical Oncology. The aim of this trial was to see whether doctors could select the most effective chemotherapy treatment for advanced lung cancer patients. 

Published: Jan 13, 2017 12:07:27 PM

Light therapy set to transform prostate cancer treatment

A new non-surgical treatment for early, low-risk prostate cancer can effectively kill cancer cells while preserving healthy tissue, reports a new phase III clinical trial in 413 patients led by Professor Mark Emberton, Dean of UCL Medical Sciences and consultant urologist at UCLH. The trial was funded by STEBA Biotech which holds the commercial license for the treatment.

Published: Dec 20, 2016 10:16:16 AM

New funding for UCL cancer centres announced

The UCL Cancer Research UK Centre, led by Professors Daniel Hochhauser and Henning Walczak, and UCL's Experimental Cancer Medicine Centre (ECMC), led by Professors Tim Meyer and John Hartley, have successfully secured new funding as part of a £226 million UK investment announced by Cancer Research UK. 

Published: Dec 20, 2016 9:46:32 AM

New research leads the way in epigenomic studies

Research led by UCL and Queen Mary University of London (QMUL) scientists has identified epigenetic changes in three types of immune cell that could contribute to the development of type 1 diabetes. These changes were only found in patients with diabetes, opening the door to future biomarker development. The study, published today in Nature Communications, employed a unique experimental design that can now allow researchers to more confidently interpret results from epigenomic studies.

Published: Nov 29, 2016 6:45:50 PM

Cancer Research UK-UCL Centre

Cancer Research UK-UCL Centre

The Cancer Research UK-UCL Centre is a network and partnership between Cancer Research UK, UCL and UCL's associated Hospital Trusts. The Centre's mission is to facilitate collaboration to advance world-class translational cancer research.

Study with us

Study with us

Our education programmes reflect the depth and breadth of research expertise within the UCL Cancer Institute. Join our community of research scientists and academic clinicians through our postgraduate taught MSc Cancer or PhD studies.

Clinical Trials

Clinical Trials

The Cancer Research UK and UCL Cancer Trials Centre is one of the largest cancer trials centres in the UK. The CTC conducts multi-centre national and international phase III trials, feasibility studies and early phase I and II studies.

Our Research

Our Research

UCL is a world leader in interdisciplinary research. The UCL Cancer Institute is uniquely placed to leverage this multidisciplinary approach to advance discoveries in basic, translational and clinical cancer research.


Support our work

UCL philanthropy

Help us to continue the research that will lead to the breakthroughs in cancer therapies that will benefit the lives of cancer patients.

Taking action for equality

Athena Swan silver logo

Connect with us